Emcure Pharmaceuticals Ltd (BSE: 544210 | NSE: EMCURE) has announced the nationwide commercial rollout of Poviztra®, a semaglutide injection for chronic weight management. With this launch, Emcure becomes the first Indian pharmaceutical company to exclusively distribute and commercialise Poviztra®, which is the second branded offering of Novo Nordisk’s semaglutide injection in the Indian market.
Poviztra® is available in a convenient once-weekly pen injector across five dosage strengths—0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg. Pricing begins at ₹8,790 per month, covering four weekly doses. The advanced pen device is designed to ensure accurate dosing with ease of use, supporting better adherence and patient convenience.
The semaglutide formulation is supported by extensive clinical evidence from the global STEP and SELECT clinical trial programmes, along with strong real-world usage data. Internationally, semaglutide has close to ten years of market experience, accounting for 38 million patient-years of exposure, and is backed by a well-established safety and efficacy profile.
Poviztra® is indicated as an adjunct to calorie restriction and increased physical activity for long-term weight management in adults with a body mass index (BMI) of 30 kg/m² or higher, or 27 kg/m² or higher in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia. The therapy is also approved to reduce the risk of major adverse cardiovascular events—including cardiovascular death, non-fatal heart attack, and non-fatal stroke—in adults with established cardiovascular disease who are overweight or obese. Clinical studies have shown weight reductions of over 20% in a significant proportion of patients.
Commenting on the launch, Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharmaceuticals Ltd, said “India is grappling with a growing obesity challenge, with nearly 254 million people affected by generalised obesity and another 351 million living with abdominal obesity. The introduction of Poviztra® is an important step toward widening access to evidence-based, scientifically validated weight management therapies. Leveraging Emcure’s extensive distribution network and pan-India reach, we aim to make advanced treatments like semaglutide accessible to a larger patient population.”
Obesity is associated with more than 230 medical conditions, including cardiovascular disease, fatty liver disease, osteoarthritis of the knee, polycystic ovary syndrome, chronic kidney disease, and Alzheimer’s disease. Through the launch of Poviztra®, Emcure reinforces its focus on improving patient outcomes and addressing the rising burden of overweight and obesity in India through innovative therapies.
Emcure Pharmaceuticals Ltd (EPL), headquartered in Pune, is a leading Indian pharmaceutical company engaged in the development, manufacturing, and global marketing of a wide portfolio of pharmaceutical products. With a strong emphasis on research and development, quality, and patient-centric innovation, Emcure delivers differentiated therapies across several major therapeutic areas aimed at improving health outcomes worldwide.
